These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27003392)

  • 1. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
    Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial.
    Nabati M; Janbabai G; Esmailian J; Yazdani J
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):233-241. PubMed ID: 30599756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
    Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
    Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
    Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
    Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
    J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals.
    Beck AL; Otto ME; D'Avila LB; Netto FM; Armendaris MK; Sposito AC
    Atherosclerosis; 2012 Jun; 222(2):444-8. PubMed ID: 22554359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.
    Cardinale D; Ciceri F; Latini R; Franzosi MG; Sandri MT; Civelli M; Cucchi G; Menatti E; Mangiavacchi M; Cavina R; Barbieri E; Gori S; Colombo A; Curigliano G; Salvatici M; Rizzo A; Ghisoni F; Bianchi A; Falci C; Aquilina M; Rocca A; Monopoli A; Milandri C; Rossetti G; Bregni M; Sicuro M; Malossi A; Nassiacos D; Verusio C; Giordano M; Staszewsky L; Barlera S; Nicolis EB; Magnoli M; Masson S; Cipolla CM;
    Eur J Cancer; 2018 May; 94():126-137. PubMed ID: 29567630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).
    Bosch X; Rovira M; Sitges M; Domènech A; Ortiz-Pérez JT; de Caralt TM; Morales-Ruiz M; Perea RJ; Monzó M; Esteve J
    J Am Coll Cardiol; 2013 Jun; 61(23):2355-62. PubMed ID: 23583763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
    Dodos F; Halbsguth T; Erdmann E; Hoppe UC
    Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
    Radulescu D; Buzdugan E; Ciuleanu TE; Todor N; Stoicescu L
    J BUON; 2013; 18(4):1052-7. PubMed ID: 24344038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
    Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major.
    Karvounis HI; Zaglavara TA; Parharidis GE; Nouskas IG; Hassapopoulou EP; Gemitzis KD; Louridas GE
    Am Heart J; 2001 Feb; 141(2):281. PubMed ID: 11174351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal Myocardial Strain Indices in Children Receiving Anthracycline Chemotherapy.
    Pignatelli RH; Ghazi P; Reddy SC; Thompson P; Cui Q; Castro J; Okcu MF; Jefferies JL
    Pediatr Cardiol; 2015 Dec; 36(8):1610-6. PubMed ID: 26049414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
    Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
    BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of left ventricular systolic dysfunction by tissue Doppler imaging to detect subclinical cardiomyopathy early after anthracycline therapy.
    Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Loperfido F; Biondi-Zoccai G
    Minerva Cardioangiol; 2007 Dec; 55(6):711-20. PubMed ID: 18091640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.
    Elitok A; Oz F; Cizgici AY; Kilic L; Ciftci R; Sen F; Bugra Z; Mercanoglu F; Oncul A; Oflaz H
    Cardiol J; 2014; 21(5):509-15. PubMed ID: 24142687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.